聚焦翰宇药业"全球药柜" 多管线产品构筑竞争力

Core Viewpoint - Hanyu Pharmaceutical has signed a strategic cooperation letter with the digital asset platform KuCoin to explore the first RWA pilot project in mainland China, anchored by overseas pharmaceutical pipelines [1] Group 1: RWA Project and Assets - The RWA project is anchored by a product matrix that includes several key drugs such as Liraglutide, Semaglutide injection, and others, with partnerships established in various regions [2] - Hanyu Pharmaceutical has nearly 50 research pipelines covering cutting-edge fields like peptide drugs and small nucleic acid drugs, including significant weight-loss medications and innovative treatments for various diseases [2] - The company has established a raw material supply network covering over 20 countries in Europe, America, and Asia, with formulations authorized for entry into over 90 countries, providing a stable cash flow foundation for asset value [2] Group 2: Financial Performance - Hanyu Pharmaceutical expects to achieve a net profit attributable to shareholders of between 142 million to 162 million yuan in the first half of 2025, representing a substantial year-on-year growth of 1470.82% to 1663.89% [3] - The strong performance growth supports the company's global expansion and innovation efforts [3]